48 / 154
S18
A B S T R A C T S
S57
Pierre Soubeyran
Université de Bordeaux, Medical Oncology, Bordeaux, France
The speaker abstract has not been received at the time of
publication.
S58
Pierre Soubeyran
Université de Bordeaux, Medical Oncology, Bordeaux, France
The speaker abstract has not been received at the time of
publication.
S59
Pierre Soubeyran
Université de Bordeaux, Medical Oncology, Bordeaux, France
The speaker abstract has not been received at the time of
publication.
S60
WHO IS FIT FOR HAEMATOLOGICAL STEM CELL
TRANSPLANTATION?
Reinhard Stauder
Medical University Innsbruck, Department of Internal Medicine V
(Haematology and Oncology), Innsbruck, Austria
Blood cancer represents a typical disease of the elderly:
median age at diagnosis is 74 years in Myelodysplastic
Syndromes (MDS) and is around 70 years in frequent
malignancies like acute myeloid leukemia (AML), multiple
myeloma, diffuse large B-cell lymphoma (DLBCL) or chronic
lymphocytic leukemia (CLL). Due to demographic changes
in our societies the number of elderly blood cancer patients
is increasing strongly. Geriatric assessment (GA) has been
introduced in hematological malignancies and reveals a
prevalence of impairments in elderly blood cancer patients in
~25–50%. Few studies have so far demonstrated the application
of geriatric interventions based on GA. Several analyses have
given evidence, that impairments in distinct dimensions of
GA impact the clinical outcome of patients. Importantly, two
studies have shown that evaluation of impairments is superior
to doctor´s best choice. The prediction of chemotherapy
toxicity has been elucidated so far predominantly in solid
tumors. However, valid data in the evaluation of therapy
tolerance in hematological malignancies are lacking so far.
Several societies including SIOG and NCCN have started to
integrate GA in recommendations and guidelines.
In summary, the integration of GA has revealed restrictions
in a relevant proportion of patients and GA represents a
relevant prognostic factor. The integration of GA in prediction
of tolerance to therapy as well as the integration of GA in
recommendations of international societies has just started,
represents a relevant challenge for the future and offers
enhanced opportunities for the individualized treatment of
elderly blood cancer patients.
Disclosure of interest:
None declared
S61
WHO IS FIT FOR HAEMATOLOGICAL STEM CELL
TRANSPLANTATION?
Reinhard Stauder
Medical University Innsbruck, Department of Internal Medicine V
(Haematology and Oncology), Innsbruck, Austria
Hematopoietic stem cell transplantation (HSCT) represents
an important option in the treatment of haematological
malignancies offering cure in a relevant proportion of
patients. Autologous HSCT represents a mainstay in therapy
of multiple myeloma, whereas allogeneic HSCT is mainly
performed in myeloid malignancies (mainly in AML and MDS)
and in lymphoid malignancies. So far application of HSCT
was restricted to younger patients due to relevant treatment-
related morbidity and mortality. Improvements in supportive
care and application of reduced-intensity conditioning
regimens have allowed patients in the sixth, and seventh
decade to be considered for HSCT.
This presentation will review current results of HSCT in
elderly blood cancer patients. Emphasis will be put on patient
selection and the possible integration of geriatric assessment
in pre-HSCT evaluation and decision-making.
Disclosure of interest:
None declared
S62
HEALTH ECONOMICS
Clémence Thébaut
Limoges University (Lecturer Senior)/Dauphine University
(Associate researcher), Paris, France
The aim of the presentation is to describe the available
data about cost/effectiveness ratio in oncogeriatrics drugs,
to analyse the specific methodological issues raised by the
assessment of these drugs and highlight the controversies at
stakes regarding the public funding given the growing size of
the target population.
Disclosure of interest:
None